The DOI matches its Crossref record; 77 of the 78 references it cites were found in a registry or an index.
Genome-Informed Targeted Therapy for Osteosarcoma
Open accessAbstract
Osteosarcoma is a highly aggressive cancer for which treatment has remained essentially unchanged for more than 30 years. Osteosarcoma is characterized by widespread and recurrent somatic copy-number alterations (SCNA) and structural rearrangements. In contrast, few recurrent point mutations in protein-coding genes have been identified, suggesting that genes within SCNAs are key oncogenic drivers in this disease. SCNAs and structural rearrangements are highly heterogeneous across osteosarcoma cases, suggesting the need for a genome-informed approach to targeted therapy. To identify patient-specific candidate drivers, we used a simple heuristic based on degree and rank order of copy-number amplification (identified by whole-genome sequencing) and changes in gene expression as identified by RNA sequencing. Using patient-derived tumor xenografts, we demonstrate that targeting of patient-specific SCNAs leads to significant decrease in tumor burden, providing a road map for genome-informed treatment of osteosarcoma. Significance: Osteosarcoma is treated with a chemotherapy regimen established 30 years ago. Although osteosarcoma is genomically complex, we hypothesized that tumor-specific dependencies could be identified within SCNAs. Using patient-derived tumor xenografts, we found a high degree of response for “genome-matched” therapies, demonstrating the utility of a targeted genome-informed approach. This article is highlighted in the In This Issue feature, p. 1
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the paitients with metastatic disease either at diagnosis or at the time of recurrence portends a dismal prognosis with 5-year survival of only 20-30% [8].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredIn the citing paper
“This genomic complexity has long been interpreted as a sign of chromosomal instability but emerging data suggest that the mechanisms triggering complexity are active early in the process of malignant transformation 35,37 .”
From Osteosarcoma (2022) · cites this paper as [35]
In the citing paper
“These rearrangements give rise to genome-wide copy number alterations, usually dominated by copy number loss, including of PTEN and CDKN2A/B, but with recurrent amplifications of MYC, VEGFA and CCNE1 (ref.35 ).”
From Osteosarcoma (2022) · cites this paper as [35]
In the citing paper
“Of note, the resulting complex genomes are subsequently maintained with some fidelity, even from diagnosis to relapse 35,37 .”
From Osteosarcoma (2022) · cites this paper as [35]
In the citing paper
“Copy number amplifications of potentially targetable genes seemed to predict sensitivity to specific agents 35 ; however, subsequent work has shown that the picture is much more complicated 9 .”
From Osteosarcoma (2022) · cites this paper as [35]
In the citing paper
“Recurrent CDK4 alterations have been described in osteosarcoma 35 .”
From Osteosarcoma (2022) · cites this paper as [35]
In the citing paper
“Furthermore, current molecular research continues to classify osteosarcomas not by histological appearance via classical osteosarcoma pathological descriptions but by proteo-genomic drivers of disease that provide further insight into disease biology and may have both prognostic and therapeutic implications 35 .”
From Osteosarcoma (2022) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
Aligning sequence reads, clone sequences and assembly contigs with BWA-MEMPreprint
Li, H. (2013) · arXiv (Cornell University) · doi:10.48550/arxiv.1303.3997 · Cited by 10,154
The Ensembl Variant Effect Predictor
McLaren, W., Gil, L., Hunt, S. E., Riat, H. S., Ritchie, G. R. S., Thormann, A., Flicek, P., & Cunningham, F. (2016) · Genome Biology · doi:10.1186/s13059-016-0974-4 · Cited by 8,099
Landscape of transcription in human cells
Djebali, S., Davis, C. A., Merkel, A., Dobin, A., Lassmann, T., Mortazavi, A., Tanzer, A., Lagarde, J., Lin, W., Schlesinger, F., et al. (2012) · Nature · doi:10.1038/nature11233 · Cited by 5,187
Aligning sequence reads, clone sequences and assembly con*gs with BWA-MEMPreprint
Li, H. (2014) · arXiv (Cornell University) · doi:10.6084/m9.figshare.963153.v1 · Cited by 5,155
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D. B., Sougnez, C. L., Gabriel, S., Meyerson, M. M., Lander, E. S., & Getz, G. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,926
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S. N., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,836
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
DELLY: structural variant discovery by integrated paired-end and split-read analysis
Rausch, T., Zichner, T., Schlattl, A., Stütz, A. M., Beneš, V., & Korbel, J. O. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts378 · Cited by 2,438
Flagged first, then by citations
1 of the 78 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 457
Augmenting L3MBTL2-induced condensates suppresses tumor growth in osteosarcoma
Zhong, L., Wang, J., Chen, W., Lv, D., Zhang, R., Wang, X., Zeng, C., He, X., Zheng, L., Gao, Y., et al. (2023) · Science Advances · doi:10.1126/sciadv.adi0889 · Cited by 22
Emerging immunotherapies in osteosarcoma: from checkpoint blockade to cellular therapies
Han, Z., Chen, G., & Wang, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1579822 · Cited by 25
Eigenbrood, J., Wong, N. W., Mallory, P. W., Pereira, J. S., Williams, D., Morris-II, D. W., Beck, J. A., Cronk, J. C., Sayers, C. M., Mendez, M., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-3723 · Cited by 24
The early evolutionary landscape of osteosarcoma provides clues for targeted treatment strategies
Kovac, M. B., Ameline, B., Ribi, S., Kováčová, M., Cross, W. C. H., Barenboim, M., Witt, O., Bielack, S., Krieg, A. H., Hartmann, W., et al. (2021) · The Journal of Pathology · doi:10.1002/path.5699 · Cited by 21
Jiang, Y., Wang, G., Mu, H., Ma, X., Wang, Z., Lv, Y. B., Zhang, T., Xu, J., Wang, J., Li, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.642134 · Cited by 21
Anlotinib for Recurrent or Metastatic Primary Malignant Bone Tumor: A Multicenter, Single-Arm Trial
Tang, L., Niu, X., Wang, Z., Cai, Q., Tu, C., Fan, Z., & Yao, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.811687 · Cited by 21
Zhang, W., Qi, L., Liu, Z., He, S., Wang, C., Wu, Y., Han, L., Liu, Z., Fu, Z., Tu, C., et al. (2023) · MedComm · doi:10.1002/mco2.317 · Cited by 20
Recent advances in understanding osteosarcoma and emerging therapies
Gaspar, N., Costa, M. E. M. D., Fromigué, O., Droit, R., Berlanga, P., & Marchais, A. (2020) · Faculty Reviews · doi:10.12703/r/9-18 · Cited by 22
Zhang, S., Chen, H., Liu, W., Fang, L., Qian, Z., Kong, R., Zhang, Q., Li, J., & Cao, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.594135 · Cited by 20
Cao, M., Zhang, J., Xu, H., Lin, Z., Chang, H., Wang, Y., Huang, X., Chen, X., Wang, H., & Song, Y. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.608368 · Cited by 20
Huang, R., Xu, M., Guo, W., Cheng, M., Dong, R., Tu, J., Xu, S., & Zou, C. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03046-x · Cited by 21
Li, W., Zhang, X., Xi, X., Li, Y., Quan, H., Liu, S., Wu, L., Wu, P., Lan, W., Shao, Y., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3066 · Cited by 19
Pandya, P. H., Cheng, L., Saadatzadeh, M. R., Bijangi‐Vishehsaraei, K., Tang, S., Sinn, A. L., Trowbridge, M. A., Coy, K. L., Bailey, B. J., Young, C., et al. (2020) · Cancers · doi:10.3390/cancers12092426 · Cited by 22
Children's Oncology Group's 2023 blueprint for research: Bone tumors
Reed, D. R., Grohar, P. J., Rubin, E. M., Binitie, O. T., Krailo, M., Davis, J. L., DuBois, S. G., & Janeway, K. A. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30583 · Cited by 21
Self-citationvan Ewijk, R., Cleirec, M., Herold, N., le Deley, M.-C., van Eijkelenburg, N., Boudou-Rouquette, P., Risbourg, S., Strauss, S. J., Palmerini, E., Boye, K., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102625 · Cited by 19
Alemi, F., Malakoti, F., Vaghari‐Tabari, M., Soleimanpour, J., Shabestani, N., Sadigh, A. R., Khelghati, N., Asemi, Z., Ahmadi, Y., & Yousefi, B. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30721 · Cited by 19
Osteosarcoma immune microenvironment: cellular struggle and novel therapeutic insights
Zhang, Y., Jiang, S., Lv, J., Feng, W., Yu, Y., & Zhao, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1584450 · Cited by 22
CDKL3 promotes osteosarcoma progression by activating Akt/PKB
He, A., Ma, L., Huang, Y., Zhang, H., Duan, W., Li, Z., Teng, F., Yuan, J., Wu, H., Liu, L., et al. (2020) · Life Science Alliance · doi:10.26508/lsa.202000648 · Cited by 19
TMED3/RPS15A Axis promotes the development and progression of osteosarcoma
Xu, W. F., Li, Y., Ye, X., Ji, Y., Chen, Y., Zhang, X., & Li, Z. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02340-w · Cited by 18
Identification of cuproptosis-related lncRNA prognostic signature for osteosarcoma
Liu, B., Liu, Z., Feng, C., Li, C., Zhang, H., Li, Z., Tu, C., & He, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.987942 · Cited by 18
Injectable rhein-assisted crosslinked hydrogel for efficient local osteosarcoma chemotherapy
Zhang, L., Liu, Y., Yao, Y., Zhou, T., Jiang, H., & Li, C. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122637 · Cited by 18
HOXC13-driven TIMM13 overexpression promotes osteosarcoma cell growth
Han, Q., Yan, P., Song, R., Liu, F., & Tian, Q. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05910-0 · Cited by 19
Integrating Radiogenomics and Machine Learning in Musculoskeletal Oncology Care
Kumar, R. R., Sporn, K., Khanna, A., Paladugu, P., Gowda, C., Ngo, A., Jagadeesan, R., Zaman, N., & Tavakkoli, A. (2025) · Diagnostics · doi:10.3390/diagnostics15111377 · Cited by 21
Chen, J., Jin, X., Mei, Y., Shen, Z., Zhu, J., Shi, H., Wang, M., Zheng, X., & Liang, G. (2021) · Cell Proliferation · doi:10.1111/cpr.13101 · Cited by 17
The Emerging Roles of LINC00665 in Human Cancers
Zhu, J., Zhang, Y., Chen, X., Bian, Y., Li, J., & Wang, K. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.839177 · Cited by 17
Predictive value of DCE-MRI and IVIM-DWI in osteosarcoma patients with neoadjuvant chemotherapy
Xia, X., Wen, L., Zhou, F., Li, J., Lü, Q., Liu, J., & Yu, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.967450 · Cited by 17
Zhou, Y., Yang, Q., Dong, Y., Ji, T., Zhang, B., Yang, C., Zheng, S., Tang, L., Zhou, C., Qian, G., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2470 · Cited by 17
Evolving copy number gains promote tumor expansion and bolster mutational diversification
Wang, Z., Xia, Y., Mills, L., Νικολακόπουλος, Α. Ν., Maeser, N., Dehm, S. M., Sheltzer, J. M., & Sun, R. (2024) · Nature Communications · doi:10.1038/s41467-024-46414-5 · Cited by 17
Green, D., van Ewijk, R., Tirtei, E., Andreou, D., Baecklund, F., Baumhoer, D., Bielack, S., Botchu, R., Boye, K., Brennan, B. M. D., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0101 · Cited by 20
Pharmacologic Inhibition of EIF4A Blocks NRF2 Synthesis to Prevent Osteosarcoma Metastasis
Lizardo, M. M., Hughes, C. S., Huang, Y. Z., Shyp, T., Delaidelli, A., Zhang, H., Shaool, S. S., Renner, A. F., Burwag, F., Sayles, L. C., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1317 · Cited by 18
Self-citationCircular RNA circ_ABCB10 in cancer
Liu, B., Zhao, N., Zhou, Y., Lu, Y., Chen, W., Huang, Z., Wang, D., Xu, Y., Yam, J. W. P., & Cui, Y. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.03.010 · Cited by 18
Estupiñán, Ó., Rendueles, C., Suárez, P., Rey, V., Murillo, D., Morís, F., Gutiérrez, G., Blanco‐López, M. C., Matos, M., & Rodrı́guez, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071358 · Cited by 17
Whittle, S. B., Offer, K., Roberts, R. D., LeBlanc, A. K., London, C. A., Majzner, R. G., Huang, A. Y.-C., Houghton, P. J., Sweet-Cordero, A., Grohar, P. J., et al. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29188 · Cited by 18
Xu, P., Lu, C., Wang, D., & Fu, D. (2021) · Microchimica Acta · doi:10.1007/s00604-021-04947-2 · Cited by 17
Singla, A. K., & Geller, D. S. (2019) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2019.09.014 · Cited by 17
Jia, Y., Chen, P., Xie, D., Chen, J., Lin, X. Y., & Xu, Y. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c08888 · Cited by 17
Ren, Z., Li, J., Zhao, S., Qiao, Q., & Li, R. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03621-y · Cited by 17
The effects of MEX3A knockdown on proliferation, apoptosis and migration of osteosarcoma cells
Wang, B., Hong, Z., Zhao, C., Bi, Q., Yuan, J., Chen, J., & Shen, Y. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01882-3 · Cited by 16
Franceschini, N., Gaeta, R., Krimpenfort, P., Bruijn, I. H. B., Kruisselbrink, A. B., Szuhai, K., Palubeckaitė, I., Cleton-Jansen, A., & Bovée, J. V. M. G. (2021) · Laboratory Investigation · doi:10.1038/s41374-021-00709-z · Cited by 16
Shi, R., Li, X., Zhang, J., Chen, F., Ma, M., Feng, Y., & Li, T. (2022) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1861 · Cited by 15
Elephant TP53-RETROGENE 9 induces transcription-independent apoptosis at the mitochondria
Preston, A. J., Rogers, A., Sharp, M., Mitchell, G., Toruno, C., Barney, B. B., Donovan, L. N., Bly, J., Kennington, R., Payne, E., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01348-7 · Cited by 16
Transcriptional regulation and therapeutic potential of cyclin-dependent kinase 9 (CDK9) in sarcoma
Walker, R. L., Hornicek, F. J., & Duan, Z. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116342 · Cited by 16
Omic approaches to pediatric bone sarcomas
Tirtei, E., Cereda, M., Luna, E. D., Quarello, P., Asaftei, S. D., & Fagioli, F. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.28072 · Cited by 16
Nie, J., Yang, T., Li, H., Ye, H., Zhong, G.-Q., Li, T., Zhang, C., Huang, W., Xiao, J., Li, Z., et al. (2021) · Journal of bone oncology · doi:10.1016/j.jbo.2021.100391 · Cited by 16
Zhang, Y., He, R. L., Xuan, L., Mao, L., Yin, Z., Zhong, X., Cao, W., Zheng, Q., & Li, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.880459 · Cited by 17
A transmembrane protein family gene signature for overall survival prediction in osteosarcoma
Du, Y., Zeng, X., Yu, W., & Xie, W. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.937300 · Cited by 16
Bishop, M. W. (2025) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2025.04.005 · Cited by 16
A Risk-Scoring Model Based on Evaluation of Ferroptosis-Related Genes in Osteosarcoma
Jiang, M., Wang, Z., He, X., Hu, Y., Xie, M., Jike, Y., Bo, Z., & Qin, W. (2022) · Journal of Oncology · doi:10.1155/2022/4221756 · Cited by 15
Liu, Z., Liu, B., Feng, C., Li, C., Wang, H., Zhang, H., Liu, P., Li, Z., He, S., & Tu, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1071636 · Cited by 15
Current topics and management of head and neck sarcomas
Kobayashi, K., Hanai, N., Yoshimoto, S., Saito, Y., & Homma, A. (2023) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad048 · Cited by 16
Targeting DNA Methylation Machinery in Pediatric Solid Tumors
Cristalli, C., & Scotlandi, K. (2024) · Cells · doi:10.3390/cells13141209 · Cited by 14
Ma, Y., Lai, P., Sha, Z., Li, B., Wu, J., Zhou, X., He, C., & Ma, X. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.01.006 · Cited by 15
Gong, Y., & Wei, Z. (2021) · Cancer Reports · doi:10.1002/cnr2.1522 · Cited by 15
Ke Cheng, X. U., Fei, W., Huo, Z., Wang, S., Li, Y., Yang, G. S., & Hong, Y. (2022) · Cancer Medicine · doi:10.1002/cam4.5025 · Cited by 14
Osteosarcoma through the Lens of Bone Development, Signaling, and MicroenvironmentPreprint
Young, E. P., Marinoff, A. E., López-Fuentes, E., & Sweet-Cordero, A. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041635 · Cited by 14
Derepressing nuclear pyruvate dehydrogenase induces therapeutic cancer cell reprogramming
Zhao, T., He, L., Wong, L. P., Mei, S., Xia, J., Xu, Y., Vranken, J. G. V., Mazzola, M. C., Chen, L., Rhee, C., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.05.009 · Cited by 14
Self-citationHuo, T., Wu, W., Chen, X., Xue, M., Liu, P., Zhang, J., Xie, Y., Wang, H., Zhou, H., Yan, Z., et al. (2025) · Intelligent Oncology · doi:10.1016/j.intonc.2025.06.005 · Cited by 15
Landuzzi, L., Ruzzi, F., Lollini, P., & Scotlandi, K. (2023) · Cancers · doi:10.3390/cancers15030588 · Cited by 15
Rey, V., Tornín, J., Alba‐Linares, J. J., Robledo, C., Murillo, D., Rodríguez, A., Gallego, B., Huergo, C., Viera, C., Braña, A., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105090 · Cited by 16
MicroRNA-431-5p Inhibits the Tumorigenesis of Osteosarcoma Through Targeting PANX3
Sun, S., Fu, L., Wang, G., Wang, J., & Xu, L. (2020) · Cancer Management and Research · doi:10.2147/cmar.s260149 · Cited by 14
Overactivation of the IGF signalling pathway in osteosarcoma: a potential therapeutic target?
Ameline, B., Kovac, M. B., Nathrath, M., Barenboim, M., Witt, O., Krieg, A. H., & Baumhoer, D. (2020) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.191 · Cited by 15
Precision Medicine in Osteosarcoma: MATCH Trial and Beyond
Tirtei, E., Campello, A., Asaftei, S. D., Mareschi, K., Cereda, M., & Fagioli, F. (2021) · Cells · doi:10.3390/cells10020281 · Cited by 13
Chu, S., Skidmore, Z. L., Kunisaki, J., Walker, J., Griffith, M., Griffith, O. L., & Bryan, J. N. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246443 · Cited by 17
Bad to the Bone: Emerging Approaches to Aggressive Bone Sarcomas
Wood, G. E., Graves, L. A., Rubin, E. M., Reed, D. R., Riedel, R. F., & Strauss, S. J. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_390306 · Cited by 16
Gross, J. M., & Hameed, M. (2025) · Surgical pathology clinics · doi:10.1016/j.path.2025.01.009 · Cited by 13
Chen, F., Liu, J., Yang, T., Sun, J., He, X., Fu, X., Qiao, S., An, J., & Yang, J. (2023) · Journal of bone oncology · doi:10.1016/j.jbo.2023.100493 · Cited by 14
PHGDH inhibition and FOXO3 modulation drives PUMA-dependent apoptosis in osteosarcoma
Oyama, T., Brashears, C. B., Rathore, R., Benedict-Hamilton, H. M., Caldwell, K. E., Dirckx, N., Hawkins, W. G., & Tine, B. A. V. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07378-6 · Cited by 13
Peng, Y.-X., Yu, B., Qin, H., Li, X., Liang, Y., & Quan, Z. (2020) · PeerJ · doi:10.7717/peerj.8489 · Cited by 13
Aberrant epigenetic silencing of neuronatin is a frequent event in human osteosarcoma
Saeed, H., Sinha, S., Mella, C., Kuerbitz, J., Cales, M. L., Steele, M. A., Stanke, J. J., Damron, D. S., Safadi, F. F., & Kuerbitz, S. J. (2020) · Oncotarget · doi:10.18632/oncotarget.27583 · Cited by 13
Identification of two immune subtypes in osteosarcoma based on immune gene sets
Yang, M., Cao, Y., Wang, Z., Zhang, T., Hua, Y., & Cai, Z. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107799 · Cited by 13
Ji, T., Shi, Q., Mei, S., Xu, J., Liang, H., Xie, L., Ren, T., Sun, K., Li, D., Tang, X., et al. (2023) · Oncogenesis · doi:10.1038/s41389-023-00474-2 · Cited by 12
From biology to personalized medicine: Recent knowledge in osteosarcoma
Mohr, A., Costa, M. E. M. D., Fromigué, O., Audinot, B., Balde, T., Droit, R., Abbou, S. D., Khneisser, P., Berlanga, P., Pérez, E., et al. (2024) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2024.104941 · Cited by 13
Polydatin: A natural compound with multifaceted anticancer properties
Imtiyaz, K., Shafi, M., Fakhri, K. U., Uroog, L., Zeya, B., Anwer, S. T., & Rizvi, M. M. A. (2024) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2024.06.006 · Cited by 15
Ayub, A., Hasan, M. K., Mahmud, Z., Hossain, M. S., & Kabir, Y. (2024) · Medical Oncology · doi:10.1007/s12032-024-02417-2 · Cited by 13
Ma, H., Dean, D. C., Wei, R., Hornicek, F. J., & Duan, Z. (2021) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x21995069 · Cited by 12
RetractedPersha, H. E., Kato, S., De, P. K., Adashek, J. J., Sicklick, J. K., Subbiah, V., & Kurzrock, R. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01344-x · Cited by 13
SOX9 is a key component of RUNX2-regulated transcriptional circuitry in osteosarcoma
Kim, Y., Tseng, Y., Ayaz, G., Wang, S., Yan, H., du Bois, W., Yang, H. H., Zhen, T., Lee, M. P., Liu, P., et al. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01088-2 · Cited by 12
Liu, W., Wang, R., Zhang, Y., Wang, H., Huang, Z., Jin, T., Yang, Y., Sun, Y., Cao, S., & Niu, X. (2021) · Cancer Genetics · doi:10.1016/j.cancergen.2021.05.013 · Cited by 12
Tao, Y., Li, L., Yang, X., Yin, S., Zhang, Z., Wang, H., Pu, R., Wang, Z., Zhang, Q., Mu, H., et al. (2024) · Frontiers in Chemistry · doi:10.3389/fchem.2024.1386076 · Cited by 12
Clinical Differences Among Histological Categories of Sarcoma: Insights from 97,062 Patients
Han, Y., Shah, A., Yao, Y., Mutter, R. W., & Xu‐Welliver, M. (2025) · Cancers · doi:10.3390/cancers17101706 · Cited by 11
Self-citationChromoanagenesis in Osteosarcoma
Li, G., Wu, N., Ghabrial, J., Stinnett, V., Klausner, M., Morsberger, L. A., Long, P., Baraban, E. G., Gross, J. M., & Zou, Y. S. (2025) · Biomolecules · doi:10.3390/biom15060833 · Cited by 11
Aberrant EZHIP expression drives tumorigenesis in osteosarcoma
Jawhar, W., Danieau, G., Annett, A., Ishii, T., Bajic, A., Castillo-Orozco, A., Krug, B., Faucher-Jabado, Y., Seyedmoomenkashi, J., Saquib, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61558-8 · Cited by 11
López-Fuentes, E., Clugston, A. S., Lee, A. G., Sayles, L. C., Sorensen, N., Ventura, M. V. P., Leung, S. G., Dinh, T., Breese, M. R., & Sweet-Cordero, A. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0237 · Cited by 16
Self-citationThe analysis of the pyroptosis-related genes and hub gene TP63 ceRNA axis in osteosarcoma
Han, J., Hu, Y., Ding, S., Liu, S., & Wang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.974916 · Cited by 12
Tang, X., Luo, L., Li, Y., Wu, H., Hu, Q., Yue, H., He, X., Zou, J., & Min, S. (2020) · Aging · doi:10.18632/aging.202258 · Cited by 11
Costa, M. E. M. D., Droit, R., Khneisser, P., Gomez‐Brouchet, A., de Beaumais, T. A., Nolla, M., Signolles, N., Torrejon-Diaz, J., Lombard, B., Loew, D., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1166063 · Cited by 10
Xia, M., Tong, S., & Gao, L. (2024) · Biomedicines · doi:10.3390/biomedicines12010092 · Cited by 10
Song, P., Xie, Z., Chen, C., Chen, L., Wang, X., Wang, F., Xie, X., Hong, X., Wang, Y., & Wu, X. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-5086 · Cited by 10
ZCCHC12 promotes the progression of osteosarcoma via PI3K/AKT pathway
Cui, Y., & Dong, Y.-Y. (2022) · Aging · doi:10.18632/aging.204296 · Cited by 10
Transformed Canine and Murine Mesenchymal Stem Cells as a Model for Sarcoma with Complex Genomics
Franceschini, N., Verbruggen, B., Tryfonidou, M. A., Kruisselbrink, A. B., Baelde, H. J., de Visser, K. E., Szuhai, K., Cleton-Jansen, A., & Bovée, J. V. M. G. (2021) · Cancers · doi:10.3390/cancers13051126 · Cited by 10
Anderson, C. J., Yang, H., Parsons, J., Ahrens, W. A., Jagosky, M. H., Hsu, J. H., Patt, J. C., Kneisl, J. S., & Steuerwald, N. M. (2025) · Clinical Orthopaedics & Related Research · doi:10.1097/corr.0000000000003161 · Cited by 10
Genome-wide enhancer RNA profiling adds molecular links between genetic variation and human cancers
Cai, Y., Lu, Z.-Q., Li, B., Huang, J., Zhang, M., Chen, C., Fan, L.-Y., Ma, Q., He, C.-Y., Chen, S., et al. (2024) · Military Medical Research · doi:10.1186/s40779-024-00539-2 · Cited by 10
Oblinger, J. L., Wang, J., Wetherell, G. D., Agarwal, G., Wilson, T. A., Benson, N., Fenger, J. M., Fuchs, J. R., Kinghorn, A. D., & Chang, L. (2024) · Scientific Reports · doi:10.1038/s41598-024-69171-3 · Cited by 9
Dhir, A., Hayashi, M., Bodlak, A., Oesterheld, J. E., Loeb, D. M., Mascarenhas, L., Isakoff, M. S., Sandler, E. S., Borinstein, S. C., Trucco, M. M., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1339 · Cited by 9
Zhao, W., Meng, H., Dai, Z., Zhang, L., Cheng, Z., Song, X., Xu, W., Wang, Z., Tian, K., Jiang, Y., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00732 · Cited by 10
Palmerini, E., Sapienza, M. R., Pileri, S. A., Frega, G., Righi, A., Parafioriti, A., Franchi, A., Agostinelli, C., Righi, S., Meazza, C., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0649 · Cited by 11
Decoding osteosarcoma from heterogeneity to precision therapy
Xu, Y., Bai, Y., Yang, F., Yang, B., Huang, Z., Su, L., & Peng, K. (2025) · Discover Oncology · doi:10.1007/s12672-025-04256-7 · Cited by 9
Sorafenib and Doxorubicin Show Synergistic Effects in Human and Canine Osteosarcoma Cell Lines
Yang, Y.-T., & Yuzbasiyan‐Gurkan, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169345 · Cited by 9
Generation and characterization of patient-derived xenografts from patients with osteosarcoma
Chen, F., Zhang, Z., Shen, R., Chen, M., Li, G., & Zhu, X. (2022) · Tissue and Cell · doi:10.1016/j.tice.2022.101911 · Cited by 9
POLE2 promotes osteosarcoma progression by enhancing the stability of CD44
Wang, B., Hu, H., Wang, X. M., Shao, Z., Shi, D., Wu, F., Liu, J., Zhang, Z., Li, J., Xia, Z., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01875-x · Cited by 8
Metadata
- Authors
- Sayles, L. C., Breese, M. R., Koehne, A. L., Leung, S. G., Lee, A. G., Liu, H.-Y., Spillinger, A., Shah, A. T., Tanasa, B., Straessler, K., Hazard, F. K., Spunt, S. L., Marina, N., Kim, G. E., Cho, S.-J., Avedian, R. S., Mohler, D. G., Kim, M.-O., DuBois, S. G., Hawkins, D. S., & Sweet-Cordero, E. A.
- Affiliations
- University of California, San Francisco (US)
- 1Division of Hematology and Oncology, Department of Pediatrics, University of California, San Francisco, California.
- Stanford Medicine (US)
- Harvard University (US)
- Seattle Children's Hospital (US)
- ORCID
- Venue
- Cancer Discovery
- Published
- 2019-01-01
- Volume
- 9
- Issue
- 1
- Pages
- 46-63
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC7134333
- OpenAlex
- W2892650455
- Cited by
- 452
- References
- 78
- Citations by year
- 2026: 48 · 2025: 59 · 2024: 67 · 2023: 84 · 2022: 63 · 2021: 63 · 2020: 52 · 2019: 14
- FWCI
- 24.47
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- HHS | National Institutes of Health (NIH) (S10OD018220, P30CA082103, 2T32OD011121-11, R25 CA180993-02)
- Hyundai Motor Group | Hyundai Motor America | Hyundai Hope On Wheels (Hope On Wheels)
- Stanford University School of Medicine (Stanford School of Medicine, Stanford University) (Morgridge Scholar Grant)
- St. Baldrick's Foundation (Team Clarkie)
- CureSearch for Children's Cancer
- Sarcoma Foundation of America (SFA)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- osteosarcoma, somatic copy number alterations, structural rearrangement, targeted therapy, patient-derived xenografts, copy number amplification, gene expression changes, oncogenic drivers
- MeSH terms
- Whole Genome Sequencing, Animals, Bone Neoplasms, Humans, Osteosarcoma, Sequence Analysis, RNA, Xenograft Model Antitumor Assays, Genomics, Mice, Genomic Structural Variation, DNA Copy Number Variations, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
